Discontinuation report ONIVYDE
| Report ID | 164803 |
| Drug Identification Number | 02467135 |
| Brand name | ONIVYDE |
| Common or Proper name | Irinotecan |
| Company Name | IPSEN BIOPHARMACEUTICALS CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | IRINOTECAN |
| Strength(s) | 4.3MG |
| Dosage form(s) | SUSPENSION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 43mg/10mL |
| ATC code | L01CE |
| ATC description | |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | |
| Actual discontinuation date | |
| Remaining supply date | |
| Discontinuation status | Reversed |
| Discontinuation decision reversal | Yes |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 5050 SATELLITE DRIVE MISSISSAUGA, ONTARIO CANADA L4W 0G1 |
| Company contact information | medinfoandsafetycanada@ipsen.com 1(855) 215-2288 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v7 | 2023-01-25 | English | Compare |
| v6 | 2022-12-22 | French | Compare |
| v5 | 2022-12-22 | English | Compare |
| v4 | 2022-08-23 | French | Compare |
| v3 | 2022-08-23 | English | Compare |
| v2 | 2022-07-18 | French | Compare |
| v1 | 2022-07-18 | English | Compare |
Showing 1 to 7 of 7